Pharnext S.C.A. (EPA:ALPHA)

Market Cap	35.00
Revenue (ttm)	171.94K
Net Income (ttm)	-27.52M
Shares Out	173.88K
EPS (ttm)	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	12,238,768
Open	0.0002
Previous Close	0.0002
Day's Range	0.0002 - 0.0002
52-Week Range	0.0001 - 2.0000
Beta	-310.14
RSI	31.42
Earnings Date	Apr 25, 2025

About Pharnext S.C.A.

Pharnext S.C.A., a clinical-stage biopharmaceutical company, engages in developing novel therapies for neurodegenerative diseases. Its products in clinical development include PXT3003, a synergistic combination of baclofen, naltrexone, and sorbitol formulated as an oral solution for the treatment of charcot-marie-tooth disease type 1A; and PXT864, a novel fixed-dose synergistic combination of baclofen and acamprosate formulated as a pill for neurodegenerative diseases. The company was incorporated in 2007 and is headquartered in Suresnes, Franc...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 19
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALPHA

Financial Performance

In 2023, Pharnext S.C.A.'s revenue was 171,938, a decrease of -97.68% compared to the previous year's 7.42 million. Losses were -27.52 million, -3.25% less than in 2022.